Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0012739 (
disseminated intravascular coagulation
)
8,673
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Evidence suggests that changes in prostaglandins and
disseminated intravascular coagulation
accompany pancreatitis. Both may induce changes in platelet function. We wished to determine if experimentally induced pancreatitis in the dog was associated with altered platelet number and function, and whether there were concomitant changes in prostaglandins. Evidence for
disseminated intravascular coagulation
in the dogs with pancreatitis were red blood cell fragmentation, increased platelet turnover indicated by macro-platelets and the transient presence of fibrin degradation products in urine. There were no significant changes in platelet count. The platelets from dogs with pancreatitis showed a functional defect characterized by significantly decreased aggregation in response to
adenosine diphosphate
, arachidonic acid, and collagen. Release of adenosine triphosphate from platelets was reduced in collagen-stimulated aggregation. There were no changes in the plasma concentrations of thromboxane B2, 6-Keto-PGF1a, and PGE2. This defect may have been due to the generation of fibrin degradation products and platelet "exhaustion".
...
PMID:Platelet function in experimentally induced pancreatitis in the dog. 308 2
Acute
disseminated intravascular coagulation
(
DIC
) is a life-threatening condition that may be encountered in many situations, especially in cases of shock with uncontrollable hemorrhage. Anisodamine, an alkaloid extracted from a Chinese herb, is well known for its dramatic therapeutic effect on
DIC
. Sixty male rabbits were used to establish an acute
DIC
model. A total of 240 blood samples were taken for laboratory assays of changes in blood coagulation factors, platelet count, platelet adhesion, platelet aggregation, malondialdehyde (MDA), thromboxane B2 (TXB2), and 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha). Changes of the microcirculatory status and the rate of the blood flow in the conjunctival capillaries of 60 rabbits were observed with WXS-II microcirculation microscope. Pathological sections of the lungs and kidneys were studied. Our investigation showed the presence of microthrombi in the microvasculature. After treatment with anisodamine, the prothrombin time stayed in the normal range, fibrinogen consumption was lessened,
adenosine-diphosphate
-induced platelet aggregation was inhibited, thromboxane B2 and malondialdehyde concentrations were significantly lower than in the control group, and the elevated quantity of 6-keto-PGF1 alpha was spared. We concluded that the anti-platelet-aggregating, microcirculation-facilitating, thromboxane-B2-inhibiting, malondialdehyde-inhibiting, and 6-keto-PGF1 alpha-sparing effects of anisodamine are the important mechanisms of its dramatic therapeutic effect on
DIC
.
...
PMID:Mechanism of the therapeutic effect of anisodamine in disseminated intravascular coagulation: study of platelet adhesion and aggregation, malondialdehyde, thromboxane B2, 6-keto-prostaglandin F1 alpha, and microcirculation. 378 Aug 90
The secretolytic agent bromhexine and its active metabolite ambroxol prevent the collagen- and
ADP
-induced decrease in circulating blood platelets in rabbits, while they do not inhibit the aggregation induced by
ADP
, collagen or arachidonic acid of human and rabbit blood platelets in vitro. Bromhexine was found to exert beneficial effects on the disturbances of pulmonary function that might be caused by a reduced surfactant production observed during thrombin-induced
disseminated intravascular coagulation
in rats. The results suggest that bromhexine has a protective effect on the acute impairment of pulmonary function due to microthrombosis.
...
PMID:[Effect of bromhexine on microthrombosis in animal experiments]. 392 41
The effect of experimental trypanosomiasis on coagulation was studied because a patient in this hospital with Rhodesian trypanosomiasis developed thrombocytopenia with
disseminated intravascular coagulation
. Rats injected intraperitoneally with this strain of Trypanosoma rhodesiense consistently developed trypanosomiasis and severe thrombocytopenia without changes in hematocrit or concentration of fibrinogen or fibrin split products. At the time of 50% mortality (4-5 days) mean platelet counts per cubic millimeter of infected rats were 18,000+/-9,000 (+/-2 SEM) compared to 1,091,000+/-128,000 in uninfected controls. In vitro, concentrated trypanosomes and trypanosomefree supernates of disrupted organisms added to normal rat, rabbit, or human blood produced platelet aggregation within 30 min. This platelet aggregation was not blocked by inhibitors of
ADP
, kinins, or early or late components of complement. In vivo thrombocytopenia also occurred in infected rabbits congenitally deficient in C6 and in infected, splenectomized rats. Although the aggregating substance obtained from disrupted trypanosomes is heat-labile, it is active in the presence of complement inhibitors, suggesting that this trypanosomal product may be a protein enzyme or toxin. Since the phenomenon is independent of immune complexes, complement,
ADP
, and kinins, it appears to represent a new mechanism of microbial injury of platelets and the induction of thrombocytopenia.
...
PMID:Thrombocytopenia in experimental trypanosomiasis. 420 22
Twenty-four patients with various types of tumors and without evidence of
consumption coagulopathy
(normal routine coagulation tests) were investigated for intraplatelet ATP,
ADP
, serotonin, beta-thromboglobulin and platelet factor 4; the percentage of light circulating platelets was also determined. Evidence for an acquired storage pool defect was found in seven patients (29%) without any correlation with the clinical status, the presence of metastases, platelet count or fibrinogen level. These results show that exhausted platelets are commonly encountered in cancerous patients even in the absence of
consumption coagulopathy
. The precise mechanism of this abnormality remains to be established.
...
PMID:Exhausted platelets in patients with malignant solid tumors without evidence of active consumption coagulopathy. 623 14
Mechanisms of coagulation and appropriate laboratory tests necessary for general surgical procedures are outlined. Physiologic features discussed include: platelet coagulation (with a brief analysis of the release and the role of prostaglandins); the equilibrium between plasma coagulation and lysis, each dependent on activators and inhibitors (a total of 4 enzymatic systems); and finally the role of the liver, lungs, and reticuloendothelial system. However, the two types of coagulation are narrowly intricated. Vessel endothelium prevents or assists platelet adhesion, coagulation, and lysis. An important feature is that total blood coagulates more rapidly than plasma. Physiopathological features described are activation of platelets or their inhibition by anti-aggregants, and induction of coagulation by endothelial lesions or eruption of an autologous or heterologous protease, as well as a brief outline of
consumption coagulopathy
and
disseminated intravascular coagulation
, and the concept of hypercoagulability. With respect to laboratory tests it is suggested that an overall picture of coagulation of total blood and not of plasma should be obtained before individual examinations for certain coagulation or lysis elements. Minimum data necessary preoperatively are the coagulation and bleeding times, completed by questioning the patient, the costs of these procedures being insignificant. If laboratory tests are necessary, these should involve a thromboelastogram of total blood, sometimes combined with a test of
ADP
-induced platelet aggregation. Certain plasma tests can provide complementary confirmatory data. These remarks are obviously applicable to general and digestive surgery only, and not to research investigations or the study of rare phenomena.
...
PMID:[Coagulation and the general surgeon. Its physiology and laboratory tests]. 665 7
The clinical value of a new in vitro test of hemostasis, which we have called Filter Bleeding Time (FBT), was determined in 59 patients referred because of a suspected bleeding disorder. FBT is based on the progressive slowing of the drop rate of citrated blood through a filter of woven Dacron under constant pressure as platelet aggregates occlude the filter. The value for FBT is defined as the time when the blood drop interval has reached 1 minute. The Mayo modification of the Ivy bleeding time (IBT) was performed in all patients; platelet response to
ADP
, collagen, epinephrine and arachidonate was performed in 24 patients. In 30 normal volunteers FBT measured 1-3 hr after venipuncture was 2.8 +/- 1.5 (means +/- 1SD) min. The FBT was prolonged in 3 of 3 patients with Glanzmann's thrombasthenia, 2 with
disseminated intravascular coagulation
, 1 with chronic lymphocytic leukemia, 1 with myelofibrosis, and 1 who had taken aspirin. In 6 patients FBT was prolonged while IBT was normal: 4 after taking aspirin, 2 with polycythemia vera. All 6 had reduced platelet aggregation (PA) to
ADP
(5 microM), collagen (2 mg/ml), epinephrine (5 microM) and/or arachidonate (1.7 mM). In 3 patients FBT was normal while IBT was abnormal: 1 with
disseminated intravascular coagulation
, 2 undiagnosed; 1 of these 3 had abnormal PA. Of 6 patients with von Willebrand's disease, FBT was prolonged in 5 and borderline in 1; IBT was prolonged in 3, normal in 1, and not done in 2 infants.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Clinical evaluation of a new test of hemostasis: the Filter Bleeding Time. 674 May 68
Hematin is clinically useful in the treatment of acute intermittent porphyria. Recently, hematin-induced coagulopathy has been reported, and a patient we treated bled during hematin therapy. On 3 separate occasions, infusions of hematin (4 mg/kg) induced thrombocytopenia, prolongation of the prothrombin time, partial thromboplastin time. Reptilase time, and apparent decreases in fibrinogen and increases in fibrin(ogen) degradation products (FDP). However, fibrinogen assayed by heat precipitation was unchanged, the protamine paracoagulation test was negative, there was no red blood cell fragmentation, and plasminogen and antithrombin III remained normal, excluding the presence of
disseminated intravascular coagulation
. Furthermore, premedication with heparin, 5000 U i.v., failed to prevent the lengthening of the Reptilase time and exacerbated the thrombocytopenia. In vitro studies revealed that hematin, 0.1 mg/ml, aggregated platelets and induced the release of 14C-serotonin and adenosine triphosphate (ATP). Hematin also aggregated washed or gel-filtered platelets but had no effect on formalin-fixed platelets. Aggregation was inhibited by aspirin (0.12 mg/ml), adenosine triphosphate, and apyrase, suggesting that hematin aggregated platelets by inducing
adenosine diphosphate
(
ADP
) release. Hematin (0.07 mg/ml) progressively inactivated thrombin and 0.1 mg/ml prolonged the Reptilase time. Thus, hematin is unique in that it both induces platelet aggregation and inhibits coagulation.
...
PMID:Hematin: unique effects of hemostasis. 682 96
Seventy-five cancer patients were evaluated on a scale of coagulation abnormalities related to
DIC
, one point given for each of the following criteria fulfilled and the score (0 to 4) being used. 1. Platelet count less than 150 x 10(3)/mu 1. 2. PT prolonged more than 1 sec over control or APTT prolonged more than 10 sec over control. 3. Fibrinogen less than 250 mg/dl (mean fibrinogen value of the cancer patients minus 1SD). 4. FDP greater than or equal to 20 micrograms/ml. The patients were distributed with 27% for score 0, 38% for 1, 20% for 2, 7% for 3 and 8% for 4. Platelet mode volume in score 4 was smaller than that of the other groups. Platelet aggregation by epinephrine was decreased in score 3 and 4 (P less than 0.01), while it was increased in score 0 (P less than 0.05).
ADP
-induced aggregation was increased in score 0 and 1 (P less than 0.01 - 0.05). The mean value of beta-thromboglobulin in cancer patients (44 +/- 24 ng/ml) was significantly higher than that of control (22 +/- 13 ng/ml) (P less than 0.01). These results suggest the existence of hyperfunction of platelets in cancer patients and possibility of a triggering mechanism of such activated platelets in the genesis of
DIC
in cancer.
...
PMID:Activation of platelets in cancer, especially with reference to genesis of disseminated intravascular coagulation. 683 44
Intravascular hemolysis and ultrastructure of erythrocytes from liver sinusoids were studied during and after infusion of Escherichia coli endotoxin in Labrador retriever dogs. Endotoxin infusion caused hemoconcentration, and induced
disseminated intravascular coagulation
(
DIC
), characterized by a rapid drop of platelet numbers, a gradual consumption of coagulation factors and activation of fibrinolysis. Advanced
DIC
and circulatory shock gradually developed, and the animals died after 7-15 h. Plasma hemoglobin concentrations did not rise for several hours, but late in the experimental period a significant intravascular hemolysis was constantly found. Circulating
adenosine diphosphate
(
ADP
) did not appear. During shock, liver biopsies revealed accumulation of erythrocytes often disintegrated within distended sinusoidal lumina. In advanced shock the fragmented erythrocyte seemed to form occlusive masses within the vessels. A fibrin-like material frequently appeared adjacent to the red cells. However, it did not have the periodicity characteristic for fibrin, and the ultrastructure of the material was very similar to that inside the erythrocytes. None of these changes were induced by saline infusion in control animals. The lack of fibrin formation and the late development of intravascular hemolysis indicate that red cell breakdown was of little importance for the initiation and progress of
DIC
.
...
PMID:Intravascular hemolysis and ultrastructural changes of erythrocytes in lethal canine endotoxin shock. 699 9
<< Previous
1
2
3
4
5
Next >>